Novo Holdings Acquires Majority Stake in Single Use Support

Pall Corporation Acquires Single Use Support GmbH from SHS

January 14, 2021

Medical Devices

Pall Corporation has acquired shares in Austrian life-science supplier Single Use Support GmbH (SUS) from SHS Gesellschaft für Beteiligungsmanagement mbH. SUS, founded in Kufstein, provides patented single-use cold-chain and fluid-handling systems used by biopharma, biotech and medical device companies worldwide; the acquisition brings SUS's transport and freeze-thaw technologies into Pall's life-science portfolio.

Novo Holdings Invests £50m in Oxford Nanopore Technologies

August 1, 2024

Biotechnology

Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.

Novo Holdings Invests $72 Million in LanzaTech

August 6, 2019

Biotechnology

Novo Holdings A/S made a $72 million Series E growth equity investment in LanzaTech to support expansion and commercialization of the company's carbon-recycling fuels and chemicals platform. Anders Bendsen Spohr of Novo Holdings will join LanzaTech's board as the investment aims to accelerate deployment of LanzaTech's sustainable fuels, chemicals and polyethylene produced from recycled carbon.

Novo Holdings Acquires Double-Digit Stake in bioMASON

December 17, 2019

Manufacturing

Novo Holdings A/S made a multimillion-dollar, double-digit equity investment in US-based bioMASON to help commercialize its bacteria-grown biocement masonry products. As part of the deal Anders Spohr of Novo Holdings will join bioMASON's board as the company scales its sustainable concrete alternative for construction and infrastructure markets.

Novo Holdings Invests $40M in Evosep

January 9, 2023

Biotechnology

Novo Holdings has invested $40 million in Evosep to accelerate the commercialization and clinical application of Evosep’s standardized proteomics liquid chromatography platform. The funds will support product development and global expansion — particularly into the U.S. — and Novo Holdings’ principal, Stephen Van Helden, will join Evosep’s board.

Novo Holdings Invests in Oxford Biomedica plc

May 28, 2019

Biotechnology

Novo Holdings A/S agreed to invest up to £53.5 million in new ordinary shares of Oxford Biomedica plc, taking up to a 10.1% stake. The proceeds will be used to repay an existing Oaktree debt facility in full and to scale Oxford Biomedica's LentiVector platform and proprietary product portfolio.